Abstract
Radical mastectomy is a primary treatment for breast cancer, but the procedure often leads to the suppression of cellular immune function, which can negatively impact a patient's quality of life (QOL) and increase the risk of postoperative complications. This protocol outlines a single-center, randomized, single-blinded trial designed to evaluate whether "press needles"—a specialized form of sustained acupuncture—can effectively modulate immune function and improve QOL in female patients following surgery.
Introduction: The Challenge of Post-Surgical Immunosuppression
While radical mastectomy is essential for many breast cancer patients, the physiological stress of surgery and anesthesia often results in significant immunosuppression. Specifically, levels of T-cells and natural killer (NK) cells frequently drop, potentially allowing circulating tumor cells to survive and increasing the risk of infections, anxiety, and insomnia.
Traditional pharmacological treatments for immunosuppression can carry adverse side effects. Acupuncture has shown potential in modulating immune responses, but standard sessions are often too brief to provide sustained benefits. This study investigates "press needles" as a non-pharmacological alternative that offers continuous stimulation to support the recovery trajectory of breast cancer survivors.
Methodology and Study Design
The study is a randomized, single-blinded, sham-controlled trial involving 78 female patients aged 18–80. Participants are randomized in a 1:1 ratio into either the press needle group or a sham control group.
- The Intervention: The experimental group receives Japanese Seirin Pyonex press needles (0.2×1.5 mm) at six specific acupoints, including Zhongwan and Zusanli. These tiny, thumbtack-like needles remain embedded for 24 hours. Patients are instructed to manually press the needles for one minute every four hours to maintain stimulation.
- The Control: The control group receives a sham press needle—a non-invasive device that mimics the sensation of the adhesive without penetrating the skin.
- Blinding: To minimize bias, patients, outcome assessors, and statisticians are blinded to the group allocation.
Study Schedule
The trial consists of an enrollment phase, a two-week treatment phase (five sessions per week), and a two-week follow-up period. The schedule of assessments is detailed in the figure below.
Outcomes and Metrics
The researchers aim to collect data on both physiological and psychological recovery markers:
- Primary Metrics: Peripheral blood T-lymphocyte subsets (CD3+, CD4+, CD8+, and the CD4+/CD8+ ratio) measured via flow cytometry.
- Secondary Metrics: Quality of life evaluated through the Karnofsky Performance Scale (KPS) and the EORTC QLQ-C30 questionnaire.
Discussion: The "Dose-Response" of Acupuncture
A key innovation of this protocol is the use of press needles to provide sustained stimulation. Unlike traditional acupuncture, which typically lasts 30 minutes, press needles remain in place for a full day. This increased "dose" of stimulation may be more effective at "untwisting" the relationship between surgical stress and cancer progression by bolstering T-cell-mediated immune responses. Furthermore, the requirement for patients to manually press the needles introduces an element of patient-led therapy that may offer additional psychological benefits.
Limitations and Future Directions
As a single-center trial based in Chengdu, China, the results may require broader multi-center validation to ensure generalizability. Additionally, while the study is rigorously blinded for assessors and patients, it is impossible to blind the acupuncturist performing the procedure. Future research will be needed to determine if the short-term immune boosts observed in this 4-week window translate into long-term improvements in cancer recurrence rates or overall mortality.
Conclusion
This study protocol provides a rigorous framework for evaluating a low-risk, non-pharmacological intervention for post-surgical breast cancer care. If successful, press needles could become a standard supportive therapy to help patients recover their immune function and improve their overall quality of life following radical mastectomy.
Summary updated